C

Canbridge Pharmaceuticals Inc
HKEX:1228

Watchlist Manager
Canbridge Pharmaceuticals Inc
HKEX:1228
Watchlist
Price: 2.26 HKD -2.59% Market Closed
Market Cap: 1.2B HKD

Canbridge Pharmaceuticals Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Canbridge Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Canbridge Pharmaceuticals Inc
HKEX:1228
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
26%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
EPS (Diluted)
-ÂĄ3
CAGR 3-Years
21%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
EPS (Diluted)
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
EPS (Diluted)
ÂĄ0
CAGR 3-Years
23%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
EPS (Diluted)
ÂĄ0
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Canbridge Pharmaceuticals Inc
Glance View

Market Cap
1.2B HKD
Industry
Biotechnology

CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.

Intrinsic Value
0.76 HKD
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Canbridge Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-1 CNY

Based on the financial report for Dec 31, 2024, Canbridge Pharmaceuticals Inc's EPS (Diluted) amounts to -1 CNY.

What is Canbridge Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-15%

Over the last year, the EPS (Diluted) growth was -17%. The average annual EPS (Diluted) growth rates for Canbridge Pharmaceuticals Inc have been 26% over the past three years , -15% over the past five years .

Back to Top